Search our Database of Scientific Publications and Authors

I’m looking for a

    8475 results match your criteria Breast cancer research and treatment[Journal]

    1 OF 170

    Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study.
    Breast Cancer Res Treat 2018 May 22. Epub 2018 May 22.
    Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA, 91010, USA.
    Background: In hormone receptor-positive advanced breast cancer, a progression-free survival benefit was reported with addition of bevacizumab to first-line letrozole. However, increased toxicity was observed. We hypothesized that functional age measures could be used to identify patients at risk for toxicity while receiving letrozole plus bevacizumab for hormone receptor-positive advanced breast cancer. Read More

    Intratumoral heterogeneity on dedicated breast positron emission tomography predicts malignancy grade of breast cancer.
    Breast Cancer Res Treat 2018 May 19. Epub 2018 May 19.
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3-Kasumi, Minami-ku, Hiroshima, 734-0037, Japan.
    Purpose: Dedicated breast positron emission tomography (DbPET) provides detailed high-resolution images and can detect intratumoral heterogeneity using F-fluorodeoxyglucose (FDG). We aimed to evaluate the correlation between FDG uptake on DbPET and the clinicopathological features of breast cancer, particularly those with an intratumoral heterogeneous distribution of FDG on DbPET.

    Methods: We evaluated 195 consecutive patients with invasive breast cancer who underwent preoperative whole-body PET (WBPET) and DbPET concurrently between January 2016 and March 2017. Read More

    Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat 2018 May 17. Epub 2018 May 17.
    Women's College Research Institute, Women's College Hospital, 76 Grenville St., 6th Floor, Toronto, ON, M5S 1B2, Canada.
    Purpose: In the general population, an early age at first full-term birth confers protection against the risk of developing breast cancer. The relationship between age at first birth and breast cancer risk is not clear for women with a mutation in the BRCA1 or BRCA2 gene. Thus, we undertook a case-control study of women with a BRCA1 or BRCA2 mutation to study the effects of age at first full-term birth matched for other reproductive factors. Read More

    Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study.
    Breast Cancer Res Treat 2018 May 17. Epub 2018 May 17.
    Discipline of Pathology, National University of Ireland, Galway, Ireland.
    Background: Several studies have demonstrated a prognostic role for stromal tumour infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC). The reproducibility of scoring sTILs is variable with potentially excellent concordance being achievable using a software tool. We examined agreement between breast pathologists across Europe scoring sTILs on H&E-stained sections without software, an approach that is easily applied in clinical practice. Read More

    Metastatic Breast Cancer Collateral Damage Project (MBCCD): Scale development and preliminary results of the Survey of Health, Impact, Needs, and Experiences (SHINE).
    Breast Cancer Res Treat 2018 May 16. Epub 2018 May 16.
    Department of Psychology, University of California, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA.
    Purpose: Until recently, people with metastatic breast cancer (MBC) had a very poor prognosis. New treatment approaches have prolonged the time that people with MBC live, but their quality of life has received less attention. Consequently, the needs and concerns across financial, vocational, psychological, social, and physical domains in MBC patients are poorly understood-particularly regarding the collateral damage or longer-term, life-altering impacts of MBC and its treatments. Read More

    Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer.
    Breast Cancer Res Treat 2018 May 16. Epub 2018 May 16.
    Multidisciplinary Breast Center, UZ Leuven, Herestraat 49, 3000, Leuven, Belgium.
    Purpose: We aimed to investigate the role of palbociclib, a first-in-class cyclin-dependent kinase 4 and 6 inhibitor, in postmenopausal women with highly pretreated endocrine therapy-resistant metastatic breast cancer (MBC).

    Methods: Between 28 September 2015 and 14 March 2017, a compassionate use program was established in the University Hospitals Leuven in which 82 postmenopausal women with estrogen receptor-positive, HER2-negative MBC were included after at least four lines of systemic treatment. The efficacy and safety analysis was performed in 82 patients who had received at least one dose of palbociclib and who had at least 6-month follow-up at the data cut-off point. Read More

    Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer.
    Breast Cancer Res Treat 2018 May 15. Epub 2018 May 15.
    Department of Surgery, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.
    Purpose: Tumour-infiltrating lymphocytes (TILs) have been shown to be prognostic for disease-free survival and predictive for the benefit of chemotherapy in patients with early breast cancer, but have not been studied for endocrine therapy.

    Experimental Design: The number of CD8-positive TILs was assessed in a subcohort of 236 patients in the Intergroup Exemestane Study. AQ After 2-3 years of adjuvant tamoxifen, AQpatients were randomized between the schemes of continuation for 5 years on tamoxifen and switching to exemestane. Read More

    Genetic dissection of the BRCA2 promoter and transcriptional impact of DNA variants.
    Breast Cancer Res Treat 2018 May 15. Epub 2018 May 15.
    Grupo de Splicing y Cáncer, Instituto de Biología y Genética Molecular (IBGM), Consejo Superior de Investigaciones Científicas (CSIC-UVa), Sanz y Forés 3, 47003, Valladolid, Spain.
    Purpose: Promoter mutations may affect transcription and can be associated with human diseases. However, the promoters of the breast cancer (BC) genes are not regularly screened. Our goal was to investigate the BRCA2 promoter in order to study a possible correlation between impaired transcription and disease. Read More

    Effect of glucocorticoid use on survival in patients with stage I-III breast cancer.
    Breast Cancer Res Treat 2018 May 14. Epub 2018 May 14.
    School of Health Care Administration, Taipei Medical University, No. 172-1, Keelung Road, Section 2, Taipei, 106, Taiwan.
    Purpose: Glucocorticoids (GCs) are commonly used in breast cancer patients to ameliorate emesis induced by chemotherapy. Some preclinical studies have suggested that systemic GCs might promote survival of estrogen receptor (ER)-negative breast cancer cells. This study aims to clarify their clinical effect on patient survival. Read More

    Concurrent risk-reduction surgery in patients with increased lifetime risk for breast and ovarian cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database.
    Breast Cancer Res Treat 2018 May 14. Epub 2018 May 14.
    Department of Surgery, University of Toronto, Toronto, ON, Canada.
    Background: Patients with genetic susceptibility to breast and ovarian cancer are eligible for risk-reduction surgery. Surgical morbidity of risk-reduction mastectomy (RRM) with concurrent bilateral salpingo-oophorectomy (BSO) is unknown. Outcomes in these patients were compared to patients undergoing RRM without BSO using a large multi-institutional database. Read More

    Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer.
    Breast Cancer Res Treat 2018 May 12. Epub 2018 May 12.
    Division of Health Policy and Insurance Research, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, 401 Park Drive, Suite 401 East, Boston, MA, 02215, USA.
    Objective: High-deductible health plans (HDHPs) have become the predominant commercial health insurance arrangement in the US. HDHPs require substantial out-of-pocket (OOP) costs for most services but often exempt medications from high cost sharing. We examined effects of HDHPs on OOP costs and utilization of adjuvant hormonal therapy (AHT), which are fundamental care for patients with breast cancer. Read More

    A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.
    Breast Cancer Res Treat 2018 May 11. Epub 2018 May 11.
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.
    Purpose: Aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) are common adverse events of AIs often leading to drug discontinuation. We initiated a prospective clinical trial to evaluate whether bisphosphonates are associated with reduced incidence of AIMSS.

    Methods: In the single-arm trial, the Zoledronic Acid Prophylaxis (ZAP) trial, we compared the incidence of AIMSS against historical controls from the Exemestane and Letrozole Pharmacogenomics (ELPh) trial. Read More

    The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
    Breast Cancer Res Treat 2018 May 11. Epub 2018 May 11.
    Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
    Purpose: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Eribulin was approved for the treatment of metastatic breast cancer through the EMBRACE trial, and a subgroup analysis in this clinical trial indicated the efficacy of eribulin in patients with TNBC. However, the prognosis of patients with TNBC is still poor due to various molecular characteristics. Read More

    Predictors of surveillance mammography outcomes in women with a personal history of breast cancer.
    Breast Cancer Res Treat 2018 May 10. Epub 2018 May 10.
    Department of Radiology, Seattle Cancer Care Alliance, University of Washington School of Medicine, Seattle, WA, USA.
    Purpose: To identify predictors of poor mammography surveillance outcomes based on clinico-pathologic features.

    Methods: This study was HIPAA compliant and IRB approved. We performed an electronic medical record review for a cohort of women with American Joint Committee on Cancer (AJCC) Stage I or II invasive breast cancer treated with breast conservation therapy who developed subsequent in-breast treatment recurrence (IBTR) or contralateral breast cancer (CBC). Read More

    Gene expression in triple-negative breast cancer in relation to survival.
    Breast Cancer Res Treat 2018 May 10. Epub 2018 May 10.
    Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
    Purpose: The identification of biomarkers related to the prognosis of triple-negative breast cancer (TNBC) is critically important for improved understanding of the biology that drives TNBC progression.

    Methods: We evaluated gene expression in total RNA isolated from formalin-fixed paraffin-embedded tumor samples using the NanoString nCounter assay for 469 TNBC cases from the Shanghai Breast Cancer Survival Study. We used Cox regression to quantify Hazard Ratios (HR) and corresponding confidence intervals (CI) for overall survival (OS) and disease-free survival (DFS) in models that included adjustment for breast cancer intrinsic subtype. Read More

    Associations of dietary intake and supplement use with post-therapy cognitive recovery in breast cancer survivors.
    Breast Cancer Res Treat 2018 May 9. Epub 2018 May 9.
    Division of Epidemiology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, 37203-1738, USA.
    Purpose: Cognitive impairment induced by cancer therapy is common and can be long lasting after completion of therapy. Little is known on factors that influence recovery from the impairment. We evaluated the associations of dietary intake and supplement use with post-therapy cognitive recovery in a large cohort of breast cancer survivors. Read More

    Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
    Breast Cancer Res Treat 2018 May 9. Epub 2018 May 9.
    Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Purpose: Seviteronel (INO-464) is an oral, selective cytochrome P450c17a (CYP17) 17,20-lyase (lyase) and androgen receptor inhibitor with in vitro and in vivo anti-tumor activity. This open-label phase 1 clinical study evaluated safety, tolerability, pharmacokinetics (PK), and activity of once-daily (QD) seviteronel in women with locally advanced or metastatic TNBC or ER+ breast cancer.

    Methods: Seviteronel was administered in de-escalating 750, 600, and 450 mg QD 6-subject cohorts. Read More

    Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database.
    Breast Cancer Res Treat 2018 May 8. Epub 2018 May 8.
    Division of Oncology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, 73, Inchon-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea.
    Purpose: We aimed to analyze the incidence, time to occurrence, and congestive heart failure (CHF) risk factors for early breast cancer patients treated with anthracycline (AC)-based chemotherapy and/or trastuzumab (T) therapy in Korea.

    Methods: We included female patients > 19 years old from the Health Insurance Review and Assessment Service database who had no prior CHF history and had been diagnosed with early breast cancer between January 2007 and October 2016.

    Results: We included 83,544 patients in our analysis. Read More

    Uptake of BRCA 1/2 and oncotype DX testing by medical and surgical oncologists.
    Breast Cancer Res Treat 2018 May 8. Epub 2018 May 8.
    Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA,, 02114, USA.
    Purpose: The diffusion of genomic testing is critical to the success of precision medicine, but there is limited information on oncologists' uptake of genetic technology. We aimed to assess the frequency with which medical oncologists and surgeons order BRCA 1/2 and Oncotype DX testing for breast cancer patients.

    Methods: We surveyed 732 oncologists and surgeons treating breast cancer patients. Read More

    SNP rs2071095 in LincRNA H19 is associated with breast cancer risk.
    Breast Cancer Res Treat 2018 May 8. Epub 2018 May 8.
    Department of Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy in Ministry of Education, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, People's Republic of China.
    Purpose: An increasing number of long intergenic non-coding RNAs (lincRNAs) appear to play critical roles in cancer development and progression. To assess the association between SNPs that reside in regions of lincRNAs and breast cancer risk, we performed a large case-control study in China.

    Methods: We carried out a two-stage case-control study including 2881 breast cancer cases and 3220 controls. Read More

    Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016).
    Breast Cancer Res Treat 2018 May 7. Epub 2018 May 7.
    Medicines Policy Research Unit, Centre for Big Data Research in Health, UNSW, Sydney, Australia.
    Purpose: Patients treated with trastuzumab for HER2-positive metastatic breast cancer (HER2+MBC) are living longer, but there is little information on their outcomes and treatment experience beyond the median survival from clinical trials and real-world observational studies. We aim to describe the real-world treatment patterns and overall survival (OS) for women surviving five or more years from initiation of trastuzumab for HER2+MBC.

    Methods: This is a retrospective, whole-of-population cohort study of women initiating trastuzumab for HER2+MBC between 2001 and 2011, followed to 2016. Read More

    A double-blind, randomised trial of a polyphenolic-rich nail bed balm for chemotherapy-induced onycholysis: the UK polybalm study.
    Breast Cancer Res Treat 2018 May 7. Epub 2018 May 7.
    Bedford and Addenbrooke's Cambridge University Hospital Trusts c/o The Primrose Unit, Kempston Rd, Bedford, MK42 9DJ, UK.
    Purpose: Nail damage is common amongst patients receiving chemotherapy causing disfigurement and pain. This investigation evaluated whether a topical balm containing steam-extracted, bioactive polyphenolic-rich herbal oils blended with organic waxes could protect the nails via their reported anti-inflammatory, analgesic, anti-oxidant and anti-microbial properties.

    Methods: 60 patients (23M, 37F) were randomised to apply (2-3/day) either the plant balm (PB) or a petroleum control (PC) to their nail beds. Read More

    Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
    Breast Cancer Res Treat 2018 May 7. Epub 2018 May 7.
    Dana Farber Cancer Institute, Boston, MA, USA.
    Purpose: Triple-negative breast cancer (TNBC) is associated with worse outcomes relative to other breast cancer subtypes. Chemotherapy remains the standard-of-care systemic therapy for patients with localized or metastatic disease, with few biomarkers to guide benefit.

    Methods: We will discuss recent advances in our understanding of two key biological processes in TNBC, homologous recombination (HR) DNA repair deficiency and host anti-tumor immunity, and their intersection. Read More

    Risk of ischemic heart disease after radiotherapy for ductal carcinoma in situ.
    Breast Cancer Res Treat 2018 May 5. Epub 2018 May 5.
    Department of Surgery and Perioperative Sciences, Umeå University, Umeå, Sweden.
    Purpose: The use of adjuvant radiotherapy (RT) in the management of ductal carcinoma in situ (DCIS) is increasing. Left-sided breast irradiation may involve exposure of the heart to ionising radiation, increasing the risk of ischemic heart disease (IHD). We examined the incidence of IHD in a population-based cohort of women with DCIS. Read More

    Incorporation of the technologist's opinion for arbitration of discrepant assessments among radiologists at screening mammography.
    Breast Cancer Res Treat 2018 May 5. Epub 2018 May 5.
    Department of Radiology, Canisius Wilhelmina Hospital, Weg Door Jonkerbos 100, 6532 SZ, Nijmegen, The Netherlands.
    Purpose: We determined whether the addition of the technologist's opinion may be helpful in deciding if discordant readings at blinded double reading should be recalled.

    Methods: A consecutive series of 99,013 digital screening mammograms, obtained between July 2013 and January 2015, were included. All mammograms were first interpreted by a technologist and then double read in a blinded fashion by a team of 13 screening radiologists. Read More

    Construction of a novel multi-gene assay (42-gene classifier) for prediction of late recurrence in ER-positive breast cancer patients.
    Breast Cancer Res Treat 2018 May 4. Epub 2018 May 4.
    Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2-2-E10 Yamadaoka, Suita-shi, Osaka, 565-0871, Japan.
    Purpose: Prediction models for late (> 5 years) recurrence in ER-positive breast cancer need to be developed for the accurate selection of patients for extended hormonal therapy. We attempted to develop such a prediction model focusing on the differences in gene expression between breast cancers with early and late recurrence.

    Methods: For the training set, 779 ER-positive breast cancers treated with tamoxifen alone for 5 years were selected from the databases (GSE6532, GSE12093, GSE17705, and GSE26971). Read More

    Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
    Breast Cancer Res Treat 2018 May 4. Epub 2018 May 4.
    University of Miami, Deerfield Beach, FL, USA.
    Purpose: To provide an overview of clinical data supporting the use of cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), metastatic breast cancer (mBC), from the perspective of the practicing oncologist community.

    Methods: A recent roundtable discussion was convened by The Breast Cancer Therapy Expert Group (BCTEG) to review existing data on this topic and its impact on their current practice.

    Results: Level 1 evidence now supports use of a CDK 4/6 inhibitor in combination with endocrine therapy for patients with HR+, HER2-, mBC. Read More

    BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients.
    Breast Cancer Res Treat 2018 May 3. Epub 2018 May 3.
    Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany.
    Purpose: BRCA1/2 mutations influence the molecular characteristics and the effects of systemic treatment of breast cancer. This study investigates the impact of germline BRCA1/2 mutations on pathological complete response and prognosis in patients receiving neoadjuvant systemic chemotherapy.

    Methods: Breast cancer patients were tested for a BRCA1/2 mutation in clinical routine work and were treated with anthracycline-based or platinum-based neoadjuvant chemotherapy between 1997 and 2015. Read More

    A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer.
    Breast Cancer Res Treat 2018 May 2. Epub 2018 May 2.
    Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 68198-6840, USA.
    Background: The role of locoregional treatment (LRT) remains controversial in de novo stage IV breast cancer (BC). We sought to analyze the role of LRT and prognostic factors of overall survival (OS) in de novo stage IV BC patients treated with LRT utilizing the National Cancer Data Base (NCDB). The objective of the current study is to create and internally validate a prognostic scoring model to predict the long-term OS for de novo stage IV BC patients treated with LRT. Read More

    Correction to: Secretomes reveal several novel proteins as well as TGF-β1 as the top upstream regulator of metastatic process in breast cancer.
    Breast Cancer Res Treat 2018 May 2. Epub 2018 May 2.
    Department of Medical Biology, School of Medicine, Dumlupınar University, Kütahya, Turkey.
    In the original publication of the article, Acknowledgement section was missed out and Table 1 was published incompletely. The Acknowledgment and complete table 1 are given in this correction. The original article has been corrected. Read More

    Menopausal hormone therapy and the risk of breast cancer by histological type and race: a meta-analysis of randomized controlled trials and cohort studies.
    Breast Cancer Res Treat 2018 Apr 30. Epub 2018 Apr 30.
    Graduate School of Industrial Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea.
    Purpose: This meta-analysis investigated the association between the risk of breast cancer and hormone replacement therapy (HRT). Various stratified analyses were performed according to race (Asian/Westerner), HRT type [all hormone therapies, estrogen-only therapy (ET), or combined estrogen-progestin therapy (EPT)], histological breast cancer type (ductal/lobular/mixed ductal-lobular), and estrogen receptor status (ER-positive/ER-negative).

    Methods: A literature search was performed using Pubmed, Embase, and KoreaMed. Read More

    FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment.
    Breast Cancer Res Treat 2018 Apr 26. Epub 2018 Apr 26.
    Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.
    Background: Bio-banked formalin-fixed paraffin-embedded (FFPE) tissues provide an excellent opportunity for translational genomic research. Historically matched blood has not always been collected as a source of germline DNA. This project aimed to establish if normal FFPE breast tissue could be used as an alternative to blood. Read More

    Lnc RNA H19 is associated with poor prognosis in breast cancer patients and promotes cancer stemness.
    Breast Cancer Res Treat 2018 Apr 24. Epub 2018 Apr 24.
    Department of Gastroenterological Surgery, Yokohama City University, 3-9 Fukuura, Kanazawa-ward, Yokohama, Kanagawa, 236-0004, Japan.
    Purpose: Aldehyde dehydrogenase1 (ALDH1) is widely accepted as a stem cell marker for normal breast as well as in breast cancer. Although the clinical impact of ALDH1 was observed in our previous study, we do not know how ALDH1 affects stem cell features resulting in worsening of prognosis in breast cancer. The purpose of this study is to explore ALDH1-related gene and its function on cancer stem cell (CSC). Read More

    Impact of port site scar on perception of patients with breast cancer: patient-reported outcomes.
    Breast Cancer Res Treat 2018 Apr 24. Epub 2018 Apr 24.
    John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA, 90404, USA.
    Purpose: As the number of survivors continues to increase with improvements in breast cancer treatment, greater emphasis has been placed on the aesthetic outcome following breast surgery. Effort is made to minimize scarring on the breast, yet patients who require a port for treatment inevitably have a scar on the upper chest from the port itself. We hypothesized that patients with breast cancer are conscious of their port scars, and if given a choice would prefer placement of the port in the arm rather than the chest. Read More

    Physician peer group characteristics and timeliness of breast cancer surgery.
    Breast Cancer Res Treat 2018 Apr 24. Epub 2018 Apr 24.
    Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, Yale Cancer Center and Yale School of Medicine, New Haven, CT, USA.
    Purpose: Little is known about how the structure of interdisciplinary groups of physicians affects the timeliness of breast cancer surgery their patients receive. We used social network methods to examine variation in surgical delay across physician peer groups and the association of this delay with group characteristics.

    Methods: We used linked Surveillance, Epidemiology, and End Results-Medicare data to construct physician peer groups based on shared breast cancer patients. Read More

    Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy.
    Breast Cancer Res Treat 2018 Apr 24. Epub 2018 Apr 24.
    Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX, USA.
    Purpose: This is the largest study to date evaluating response rates and pathologic complete response (pCR) and predictors thereof, based on molecular subtype, in women with breast cancer having undergone neoadjuvant chemotherapy (NC).

    Methods: The National Cancer Database was queried for women with cT1-4N1-3M0 breast cancer having received NC. Patients were divided into four subtypes: luminal A, luminal B, Her2, or triple negative (TN). Read More

    The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer.
    Breast Cancer Res Treat 2018 Apr 24. Epub 2018 Apr 24.
    Women's College Research Institute, 76 Grenville Street, Toronto, ON, M5S 1B1, Canada.
    Background: In patients with breast cancer, increasing tumour size at diagnosis is associated with an increased likelihood of axillary lymph node involvement and increased breast cancer-specific mortality. However, this relation is based on studies which combine all tumours smaller than 1.0 cm in a single category and all tumours larger than 5. Read More

    Bilateral mastectomies: can a co-surgeon technique offer improvements over the single-surgeon method?
    Breast Cancer Res Treat 2018 Apr 23. Epub 2018 Apr 23.
    Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
    Purpose: Bilateral mastectomy (BM) is traditionally performed using a single-surgeon (SS) technique (SST); a co-surgeon (CS) technique (CST), where each attending surgeon concurrently performs a unilateral mastectomy, offers an alternative approach. We sought to compare the CST and SST for BM with respect to operative times and complications.

    Methods: Patients undergoing BM without reconstruction at our institution between 2005 and 2015 were identified using operative caselogs and stratified into CS- and SS-cohorts. Read More

    Uptake of breast cancer preventive therapy in the UK: results from a multicentre prospective survey and qualitative interviews.
    Breast Cancer Res Treat 2018 Apr 24. Epub 2018 Apr 24.
    Leeds Institute of Health Sciences, University of Leeds, Worsley Building, Clarendon Way, Leeds, LS2 9NL, UK.
    Purpose: Uptake of preventive therapy for women at increased breast cancer risk in England is unknown following the introduction of UK clinical guidelines in 2013. Preventive therapy could create socioeconomic inequalities in cancer incidence if it is more readily accepted by particular socio-demographic groups. In this multicentre study, we investigated uptake of tamoxifen and evaluated socio-demographic and clinical factors associated with initiation. Read More

    A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.
    Breast Cancer Res Treat 2018 Apr 19. Epub 2018 Apr 19.
    University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA.
    Purpose: The Janus-associated kinase (JAK)/signal transducer and activator of transcription pathway is a key regulator of inflammatory signaling, associated with tumorigenesis, cell survival, and progression. This randomized phase 2 trial evaluated the efficacy and safety of the addition of ruxolitinib, a JAK1/JAK2 inhibitor, to capecitabine in patients with HER2-negative advanced breast cancer and high systemic inflammation (modified Glasgow Prognostic Score [mGPS] ≥ 1).

    Methods: Patients with ≤ 2 prior chemotherapy regimens for advanced or metastatic disease or hormone receptor-positive patients with disease progression on prior hormonal therapies were randomized 1:1 to 21-day cycles of ruxolitinib (n = 76) or placebo (n = 73) plus capecitabine. Read More

    Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system.
    Breast Cancer Res Treat 2018 Apr 18. Epub 2018 Apr 18.
    Division of Research, Kaiser Permanente Northern California, 2000 Broadway, 5th floor, Oakland, CA, USA.
    Purpose: We evaluated associations between personal and clinical social support and non-adherence to adjuvant endocrine therapy (AET) in a large, Northern California breast cancer (BC) cohort from an integrated healthcare network.

    Methods: This study included 3382 women from the Pathways Study diagnosed from 2005 to 2013 with stages I-III hormone receptor-positive BC and who responded to the Medical Outcomes Study Social Support and Interpersonal Processes of Care surveys, approximately 2 months post-diagnosis. We used logistic regression to evaluate associations between tertiles of social support and non-initiation (< 2 consecutive prescription fills within a year after diagnosis). Read More

    Effects of physical exercise after treatment of early breast cancer: systematic review and meta-analysis.
    Breast Cancer Res Treat 2018 Apr 13. Epub 2018 Apr 13.
    Pathology Post-Graduate Program - Universidade Federal de Ciências da Saúde de Porto Alegre, 245, Sarmento Leite Street - Centro Histórico, Porto Alegre, RS, 90050-170, Brazil.
    Purpose: Randomized clinical trials are inconclusive regarding the role of physical exercise in anthropometric measurements, quality of life, and survival in breast cancer patients. Our aim was to conduct a systematic review and meta-analysis to assess the effects of physical exercise on these outcomes in women who went through curative treatment of early-stage breast cancer.

    Methods: Pubmed, Embase, Cochrane Library were searched for randomized clinical trial comparing physical exercise (counseling or structured programs with supervised/individualized exercise sessions) with usual care in women that went through for breast cancer treatment. Read More

    Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.
    Breast Cancer Res Treat 2018 Apr 13. Epub 2018 Apr 13.
    Department of Gynecology, Universitätsklinikum Ulm, Prittwitzstraße 43, 89075, Ulm, Germany.
    Purpose: Evaluate patient-reported outcomes (PROs) for postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer treated with first-line ribociclib plus letrozole.

    Methods: In the phase III MONALEESA-2 study (NCT01958021), 668 patients were randomized 1:1 to ribociclib (600 mg/day; 3-weeks-on/1-week-off) plus letrozole (2.5 mg/day) or placebo plus letrozole. Read More

    An estrogen-related lifestyle score is associated with risk of postmenopausal breast cancer in the PLCO cohort.
    Breast Cancer Res Treat 2018 Apr 12. Epub 2018 Apr 12.
    Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
    Purpose: Healthy or unhealthy lifestyle behaviors are often adopted together. We aimed to investigate the combined effect of estrogen-related lifestyle factors on postmenopausal breast cancer risk.

    Methods: Data from 27,153 women enrolled in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial were used. Read More

    Correction to: Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease.
    Breast Cancer Res Treat 2018 Apr 11. Epub 2018 Apr 11.
    Department of Epidemiology and Population Health, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, NY, 10461, USA.
    The third category for extent of involution in Table 4 was published incorrectly in the original publication. The correct classification is ≥ 75% and the corrected Table 4 is given below. Read More

    Pre-diagnostic changes in body mass index and mortality among breast cancer patients.
    Breast Cancer Res Treat 2018 Apr 10. Epub 2018 Apr 10.
    Danish Cancer Society Research Center, Strandboulevarden 49, 2100, Copenhagen Ø, Denmark.
    Purpose: We investigated whether changes in body mass index (BMI) before a breast cancer diagnosis affected mortality and whether trajectories more accurately predict overall mortality compared to a single measure of BMI.

    Methods: Our prospective cohort comprised 2012 women with breast cancer who reported their weight in each decade from 20 to 50-64 years of age. We used trajectory analysis to identify groups with similar development patterns in BMI and Cox proportional hazards models to examine the association between trajectory groups and mortality, and interactions with oestrogen receptor status and smoking. Read More

    Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis.
    Breast Cancer Res Treat 2018 Apr 9. Epub 2018 Apr 9.
    Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham, UK.
    Background: The functions of many proteins are tightly regulated with a complex array of cellular functions including ubiquitination. In cancer cells, aberrant ubiquitination may promote the activity of oncogenic pathways with subsequent tumour progression. Kelch-like family member 7 (KLHL7) is involved in the regulation of ubiquitination and may play a role in breast cancer (BC). Read More

    Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer.
    Breast Cancer Res Treat 2018 Apr 5. Epub 2018 Apr 5.
    Department of Cancer Biology, Beckman Research Institute of the City of Hope, 1500 East Duarte Road, Kaplan CRB, Room 2002C, Duarte, CA, USA.
    Purpose: HR+/HER2- aromatase inhibitor-resistant metastatic breast cancer can be treated with everolimus and a second AI until the cancer recurs. Targeting these everolimus-resistant patients with the latest standard of care, CDK4/6 inhibitors, has not been clearly addressed. Understanding the signaling transduction pathways, which everolimus resistance activates, will elucidate the mechanisms and offer treatment strategies of everolimus resistance. Read More

    1 OF 170